1064-nm Nd:YAG laser as an antibiotic-sparing treatment option for inflammatory acne: a narrative review and evidence-informed practical treatment framework

Stefan Bigge; Bianca Bigge

doi:10.18203/issn.2455-4529.IntJResDermatol20262319

Authors

Stefan Bigge Hautarztpraxis Bigge/Ungerechts, Cologne, Germany
Bianca Bigge Hautarztpraxis Bigge/Ungerechts, Cologne, Germany

DOI:

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20262319

Keywords:

Acne vulgaris, Inflammatory acne, 1064-nm, Nd:YAG laser, Antibiotic stewardship, Antibiotic-sparing, Laser therapy, Energy-based devices, Skin of color

Abstract

Antibiotic stewardship has become an increasingly important consideration in acne management. Systemic antibiotics remain useful for selected patients with inflammatory acne, but repeated or prolonged exposure raises concerns regarding antimicrobial resistance, microbiome disruption, tolerability, and adherence. Non-antibiotic procedural approaches may therefore have a role as adjunctive or antibiotic-sparing options in carefully selected patients. To review the clinical rationale, evidence base, safety considerations, and practical integration of 1064-nm neodymium-doped yttrium aluminum garnet (Nd:YAG) laser therapy for inflammatory acne. A narrative PubMed-based review was conducted focusing on 1064-nm Nd:YAG laser therapy for active acne, antibiotic stewardship, standard acne therapy, device-based acne treatment, safety in skin of color, isotretinoin and energy-based devices, and competing technologies. Studies exclusively addressing acne scars, post-acne erythema, hidradenitis suppurativa, or acne keloidalis nuchae were excluded from the core evidence synthesis. Evidence for 1064-nm Nd:YAG laser therapy includes microsecond-domain 650-usec studies, millisecond long-pulsed protocols, Q-switched and carbon-assisted approaches, and comparative studies against other procedural modalities. A sham-controlled randomized trial supports 650-usec 1064-nm treatment, and prospective and retrospective studies report improvement across a range of acne severities and Fitzpatrick skin types. Comparative studies suggest benefit for inflammatory lesions, but protocols, outcomes, comparators, and follow-up periods remain heterogeneous. No study has definitively demonstrated reduced cumulative antibiotic exposure as a predefined endpoint. 1064-nm Nd:YAG laser therapy should not be presented as a replacement for guideline-based pharmacologic acne treatment. The most defensible role is as an adjunctive or potential antibiotic-sparing procedural option for selected patients with inflammatory acne. Future trials should prospectively measure antibiotic exposure, relapse, maintenance needs, patient-reported outcomes, and cost-effectiveness.

References

Reynolds RV, Yeung H, Cheng CE, Cook-Bolden F, Desai SR, Druby K, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90(5):1006.e1-30.

National Institute for Health and Care Excellence. Acne vulgaris: management. NICE guideline NG198. London: NICE, 2021. Available at: https://www.nice.org.uk/guidance/ng198. Accessed on 18 May 2026.

Mavranezouli I, Daly CH, Welton NJ, Deshpande S, Berg L, Bromham N, et al. A systematic review and network meta-analysis of topical pharmacological, oral pharmacological, physical and combined treatments for acne vulgaris. Br J Dermatol. 2022;187(5):639-49.

Barbieri JS, Spaccarelli N, Margolis DJ, James WD. Approaches to limit systemic antibiotic use in acne: systemic alternatives, emerging topical therapies, dietary modification, and laser and light-based treatments. J Am Acad Dermatol. 2019;80(2):538-49.

Dessinioti C, Katsambas A. Antibiotics and antimicrobial resistance in acne: epidemiological trends and clinical practice considerations. Yale J Biol Med. 2022;95(4):429-43.

Kesty K, Goldberg DJ. 650 usec 1064 nm Nd:YAG laser treatment of acne: a double-blind randomized control study. J Cosmet Dermatol. 2020;19(9):2295-300.

Saedi N, Griffin T, Kelly S. Treatment of mild to severe acne vulgaris with a 650-microsecond 1064-nm Nd:YAG laser. J Drugs Dermatol. 2024;23(11):957-64.

Olugbade ID, Petty AC, Imahiyerobo-Ip J. Treatment of acne vulgaris with a 650-ms, 1064-nm Nd:YAG laser: a retrospective study. J Cosmet Dermatol. 2025;24(2):e16711.

Chalermsuwiwattanakan N, Rojhirunsakool S, Kamanamool N, Kanokrungsee S, Udompataikul M. The comparative study of efficacy between 1064-nm long-pulsed Nd:YAG laser and 595-nm pulsed dye laser for the treatment of acne vulgaris. J Cosmet Dermatol. 2021;20(7):2108-15.

Ibrahim AM, Omar GAB, Hamdino M. Long-pulsed Nd:YAG laser (1064 nm) versus intralesional botulinum toxin type A in acne vulgaris therapy: a split-face study. Int J Dermatol. 2023;62(6):822-30.

Moftah NH, Mansour AM, Ibrahim SMA. Clinical evaluation of efficacy of intralesional platelet-rich plasma injection versus 1064 nm long-pulsed Neodymium:YAG laser in the treatment of inflammatory acne vulgaris in adolescent and post-adolescent patients: a prospective randomized split-face comparative study. Lasers Med Sci. 2022;37(5):2471-78.

Hammoda TM, Elmetwally AS, Ibrahim SM, Mohsen NA. Fractional CO2 laser versus 1064-nm long-pulsed Nd:YAG laser in treatment of acne vulgaris: a randomized split-face study. Lasers Med Sci. 2023;38(1):189.

Jung JY, Hong JS, Ahn CH, Yoon JY, Kwon HH, Suh DH. Prospective randomized controlled clinical and histopathological study of acne vulgaris treated with dual mode of quasi-long pulse and Q-switched 1064-nm Nd:YAG laser assisted with a topically applied carbon suspension. J Am Acad Dermatol. 2012;66(4):626-33.

Maghsoodloo D, Jafarzadeh A, Ghassemi M, Sadeghzadeh-Bazargan A, Goodarzi A. Comparison of the efficacy of Q-switched versus long-pulsed fractional 1064 nm Nd:YAG laser in the treatment of active facial acne: a pilot, double-blind, randomized, controlled, split-face study. Health Sci Rep. 2026;9(4):e72354.

Li MK, Liu C, Hsu JTS. The use of lasers and light devices in acne management: an update. Am J Clin Dermatol. 2021;22(6):785-800.

Jafarzadeh A, Heidari S, Omid R, Goodarzi A. Systematic review of vascular lasers for the treatment of inflammatory active acne vulgaris. Lasers Med Sci. 2025;40(1):168.

Wiznia LE, Stevenson ML, Nagler AR. Laser treatments of active acne. Lasers Med Sci. 2017;32(7):1647-58.

Haedersdal M, Togsverd-Bo K, Wulf HC. Evidence-based review of lasers, light sources and photodynamic therapy in the treatment of acne vulgaris. J Eur Acad Dermatol Venereol. 2008;22(3):267-78.

Ingram JR, Grindlay DJC, Williams HC. Management of acne vulgaris: an evidence-based update. Clin Exp Dermatol. 2010;35(4):351-4.

Pulumati A, Chen Y, Leu S, Zachary CB. Targeting sebaceous glands: a review of selective photothermolysis for acne vulgaris treatment. Arch Dermatol Res. 2024;316(7):356.

Sakamoto FH, Doukas AG, Farinelli WA, Tannous ZS, Anderson RR. Selective photothermolysis to target sebaceous glands: theoretical estimation of parameters and preliminary results using a free electron laser. Lasers Surg Med. 2012;44(2):175-83.

Scopelliti MG, Kothare A, Karavitis M. A novel 1726-nm laser system for safe and effective treatment of acne vulgaris. Lasers Med Sci. 2022;37(9):3639-47.

Goldberg D, Kothare A, Doucette M, Karavitis M, Scopelliti M. Selective photothermolysis with a novel 1726 nm laser beam: a safe and effective solution for acne vulgaris. J Cosmet Dermatol. 2023;22(2):486-96.

Alexiades M, Kothare A, Goldberg D, Dover JS. Novel 1726 nm laser demonstrates durable therapeutic outcomes and tolerability for moderate-to-severe acne across skin types. J Am Acad Dermatol. 2023;89(4):703-10.

Goldberg D, Ronan S, Bhatia AC, Dhawan S, Green JB, Kilmer SL, et al. Safe and effective acne treatment across skin types with a 1726-nm sebum-selective laser: one-year data from a prospective multicenter study. J Am Acad Dermatol. 2026;94(2):244-53.

Hu S, Atmakuri M, Rosenberg J. Adverse events of nonablative lasers and energy-based therapies in subjects with Fitzpatrick skin phototypes IV to VI: a systematic review and meta-analysis. Aesthet Surg J. 2022;42(6):NP394-403.

Xu Y, Wang H, Guo L, Hamblin MR, Wen X. Combinations of energy-based devices plus isotretinoin for management of acne and acne scars: a systematic review. J Cosmet Dermatol. 2024;23(10):3090-101.

Handler MZ, Bloom BS, Goldberg DJ. Energy-based devices in treatment of acne vulgaris. Dermatol Surg. 2016;42(5):573-85.